18 min listen
PrEP: Are We Educating Patients Effectively? - Frankly Speaking Ep 268
PrEP: Are We Educating Patients Effectively? - Frankly Speaking Ep 268
ratings:
Length:
10 minutes
Released:
Mar 21, 2022
Format:
Podcast episode
Description
Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-268
Overview: This episode will help bring awareness to the importance of educating patients about post-exposure prophylaxis (PrEP) in the primary care setting. This talk will also discuss how to reduce the stigma surrounding this prevention method. Finally, you will hear about the newly FDA approved PrEP treatment option that could potentially improve outcomes for patients.
Episode resource links:
https://www.healio.com/news/infectious-disease/20211220/fda-approves-first-longacting-injectable-for-hiv-prevention
Philbin, M. M., Parish, C., Kinnard, E. N., Reed, S. E., Kerrigan, D., Alcaide, M. L., ... & Metsch, L. R. (2021). Interest in long-acting injectable pre-exposure prophylaxis (LAI PrEP) among women in the women’s interagency HIV study (WIHS): a qualitative study across six cities in the United States. AIDS and Behavior, 25(3), 667-678.
Kim Y. S. (2021). Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention. Infection & chemotherapy, 53(4), 686–695. https://doi.org/10.3947/ic.2021.0136
CDC Practice guidelines https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
Guest: Mariyan L. Montaque, DNP, FNP-BC
Music Credit: Richard Onorato
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-268
Overview: This episode will help bring awareness to the importance of educating patients about post-exposure prophylaxis (PrEP) in the primary care setting. This talk will also discuss how to reduce the stigma surrounding this prevention method. Finally, you will hear about the newly FDA approved PrEP treatment option that could potentially improve outcomes for patients.
Episode resource links:
https://www.healio.com/news/infectious-disease/20211220/fda-approves-first-longacting-injectable-for-hiv-prevention
Philbin, M. M., Parish, C., Kinnard, E. N., Reed, S. E., Kerrigan, D., Alcaide, M. L., ... & Metsch, L. R. (2021). Interest in long-acting injectable pre-exposure prophylaxis (LAI PrEP) among women in the women’s interagency HIV study (WIHS): a qualitative study across six cities in the United States. AIDS and Behavior, 25(3), 667-678.
Kim Y. S. (2021). Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention. Infection & chemotherapy, 53(4), 686–695. https://doi.org/10.3947/ic.2021.0136
CDC Practice guidelines https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
Guest: Mariyan L. Montaque, DNP, FNP-BC
Music Credit: Richard Onorato
Released:
Mar 21, 2022
Format:
Podcast episode
Titles in the series (100)
Helping Kidney Stones Pass: Use of Alpha Antagonists – Frankly Speaking EP7: In this podcast episode, we will talk about the benefits of alpha antagonists on passing larger kidney stones as well as discuss the need for stone collection and analysis to prevent future stones. We will also learn how to effectively counsel patients a... by Frankly Speaking About Family Medicine